XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Business Segments
3 Months Ended
Sep. 30, 2025
Business Segments  
Business Segments

12.  Business Segments

We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products reporting segments. The Chief Executive Officer is the chief operating decision-maker (“CODM”) for the Company. We evaluate performance of our segments based on Adjusted EBITDA. Included in the segment Adjusted EBITDA analyses provided to the CODM is information on segment cost of sales and selling, general and administrative expenses. There are no other significant segment expense categories regularly provided to the CODM.

We calculate Adjusted EBITDA as net income plus (a) interest expense, net, (b) provision for income taxes or less benefit for income taxes, (c) depreciation and amortization, (d) other non-operating expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (e) certain items that we consider to be unusual, non-operational or non-recurring. However, some of these items may not be applicable to the calculation of Adjusted EBITDA for our segments, as we do not typically include interest, other non-operating items, or income tax-related items in our segment results.

Certain of our costs and assets are not directly attributable to a segment or segments, and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the other segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, information technology, legal, finance, human resources and business development. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included in Note 2 — Summary of Significant Accounting Policies and New Accounting Standards included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025.

For all segments, the CODM uses segment Adjusted EBITDA in the annual budgeting and quarterly forecasting process and considers budget-to-actual and current period to prior period variances to evaluate performance and allocate resources for each segment.

    

Three Months

For the Periods Ended September 30

    

2025

    

2024

Net sales

 

 

 

 

 

 

Animal Health

$

283,456

$

182,523

Mineral Nutrition

 

62,988

 

59,062

Performance Products

 

17,449

 

18,847

Total segments

$

363,893

$

260,432

 

Three Months

For the Periods Ended September 30

    

2025

2024

Animal Health

Net sales

 

$

283,456

$

182,523

Cost of sales

172,872

108,239

Selling, general and administrative expenses (1)

47,251

41,562

Add: Depreciation and amortization

11,599

7,663

Add: Acquisition-related cost of goods sold (2)

1,117

Subtract: Insurance proceeds (4)

(1,177)

Adjusted EBITDA

74,872

40,385

Mineral Nutrition

Net sales

 

62,988

59,062

Cost of sales

57,284

53,887

Selling, general and administrative expenses (1)

1,715

1,929

Add: Depreciation and amortization

534

516

Adjusted EBITDA

4,523

3,762

Performance Products

Net sales

 

17,449

18,847

Cost of sales

13,954

14,818

Selling, general and administrative expenses (1)

2,118

2,074

Add: Depreciation and amortization

226

333

Adjusted EBITDA

1,603

2,288

Adjusted EBITDA – Total segments

$

80,998

$

46,435

Reconciliation of Adjusted EBITDA to income before income taxes:

Less:

Interest expense, net

 

12,059

 

7,641

Depreciation and amortization – Total segments

 

12,359

 

8,512

Depreciation and amortization – Corporate

 

471

 

492

Corporate costs

19,140

15,779

Acquisition-related cost of goods sold

 

1,117

 

Acquisition-related transaction costs

 

258

 

3,424

Stock-based compensation expense - named executive officer awards granted in fiscal year 2024

 

179

 

179

Phibro Forward income growth initiatives implementation costs - SG&A (3)

350

Insurance proceeds (4)

(3,786)

Foreign currency losses, net

 

2,934

 

438

Income before income taxes

$

36,267

$

9,620

(1)Selling, general, and administrative expenses primarily include compensation-related expenses for employees not directly involved in the production and sale of inventory, rent expenses, research and development costs, marketing expenses, and other general and administrative expenses.
(2)Represents cost of goods sold related to the stepped-up value of inventory obtained in acquisitions.
(3)Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings.
(4)Represents insurance settlement gains, which are recorded within selling, general and administrative expenses.

 

 

The geographic location of property, plant and equipment, net and ROU operating lease assets was:

September 30, 

June 30, 

As of

    

2025

    

2025

Property, plant and equipment, net and ROU operating lease assets

 

  

 

  

United States

$

238,006

$

239,874

Israel

 

74,069

 

74,403

Brazil

 

35,394

 

34,504

Ireland

25,399

25,141

Other

 

22,058

 

22,107

$

394,926

$

396,029

 

 

Asset information is not provided for reportable segments in the information regularly provided to the CODM. Accordingly, such information is not disclosed in this footnote.